IOVA Stock: Iovance Biotherapeutics, Inc. Stock Price, Analysis & Insights
Get live iova stock price $2.31, comprehensive Iovance Biotherapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time iova stock data and investment insights.
Loading chart...
Company Overview
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Company Information
- CEO
- Frederick G. Vogt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 838
Contact Information
- Website
- https://www.iovance.com
- Address
- 825 Industrial Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Iovance Biotherapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Frederick G. Vogt, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Iovance Biotherapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 835.9 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Iovance Biotherapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Iovance Biotherapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Iovance Biotherapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Iovance Biotherapeutics, Inc.
- ⚠Investors should consider how Iovance Biotherapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
835.88M
P/E Ratio
-1.91
Beta
0.85
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 835.88M market capitalization
- Trading Volume: 83.54M shares traded today
- Price Range: 52-week range of $1.64 - $12.51
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (IOVA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 835.88M, the company represents a significant player in its market. The stock is currently trading at $2.31 with a positivedaily change of 27.62%.
The company's 838 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -1.91, beta of 0.85, and 52-week price range from $1.64 to $12.51when evaluating investment opportunities.
Why Invest in Iovance Biotherapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Frederick G. Vogt
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.